Front line treatment of elderly multiple myeloma in the era of novel agents
Marie-Dominique Venon2, Aldo M Roccaro1,3, Julie Gay2, Anne-Sophie Moreau1,2, Remy Dulery2, Thierry Facon2, Irene M Ghobrial1, Xavier Leleu1,21Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; 2Service des Maladies du Sang, Hopital Huriez, CHRU...
Guardado en:
Autores principales: | Marie-Dominique Venon, Aldo M Roccaro, Julie Gay, Anne-Sophie Moreau, Remy Dulery, et al |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c3d984edaf5f40e592669015b0aade17 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Multiple myeloma in the very elderly patient: challenges and solutions
por: Willan J, et al.
Publicado: (2016) -
Global epigenetic regulation of microRNAs in multiple myeloma.
por: Wenjing Zhang, et al.
Publicado: (2014) -
Does Ethnicity Matter in Multiple Myeloma Risk Prediction in the Era of Genomics and Novel Agents? Evidence From Real-World Data
por: Akanksha Farswan, et al.
Publicado: (2021) -
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
por: Bhutani D, et al.
Publicado: (2017) -
Multiple myeloma
por: Larisa P. Mendeleeva, et al.
Publicado: (2021)